<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327808</url>
  </required_header>
  <id_info>
    <org_study_id>TPI 1020-202</org_study_id>
    <nct_id>NCT00327808</nct_id>
  </id_info>
  <brief_title>Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma</brief_title>
  <official_title>Multi-Center, Randomized, Double-Blind, Repeated Doses Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmaxis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will look at TPI-1020 safety and tolerability in mild to moderate asthmatic
      smoker subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess and compare the safety and tolerability of inhaled TPI 1020 versus
      budesonide. Pharmacokinetic (PK) and pharmacodynamic (PD) parameters will also be studied in
      a sub-group of subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of multiple doses of TPI-1020 in subjects with asthma who smoke</measure>
    <time_frame>22 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare sputum neutrophil and eosinophil counts on Day 0 versus Day 15 and Day 22</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine pharmacodynamic effects on forced expiratory volume in 1 second (FEV1) over 8 hours on Day 1 and Day 14</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare pre-dose FEV1 measurements on multiple days throughout the study</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare peak flow measurements throughout the study</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the use of daily rescue medication (salbutamol) throughout the study</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the plasma pharmacokinetic (PK) profile on a sub-group of subjects on the first and last day of the dosing period</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPI 1020</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaler cortico.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI-1020</intervention_name>
    <description>600 mcg BID x 14 days followed by 1200 mcg BID x 7 days</description>
    <arm_group_label>Inhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>400 mcg BID x 14 days then 800 mcg/day x 7 more days</description>
    <arm_group_label>Inhaler cortico.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 18 through 65 years of age.

          -  Smoking history of more than 5 pack/years but less than 25 pack/years and who have no
             desire to quit smoking despite physician's advice and who currently smoke at least 5
             cigarettes per day.

          -  Mild to moderate, stable, allergic asthma as defined by American Thoracic Society
             (ATS) criteria 1

          -  History of episodic wheeze and shortness of breath

          -  Subjects currently and only receiving inhaled short-acting bronchodilator treatment
             for asthma.

        Exclusion Criteria:

          -  History or symptoms of significant autoimmune, hematological, or neurological disease,
             including transient ischemic attack (TIA), stroke, seizure disorder, or behavioural
             disturbances that are judged clinically significant by the Investigator

          -  History of serious adverse reaction or hypersensitivity to corticosteroids

          -  Abnormal chest X-ray that is judged clinically significant

          -  Pregnant or lactating or have positive plasma pregnancy test

          -  Use of oral/parenteral/inhaled corticosteroids within the last 28 days or injectable
             depot corticosteroids within the last 6 weeks.

          -  Use of any other asthma-related medications within 1 month of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Renzi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmaxis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 106</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARL</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7V 3Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sacre Coeur</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier St-Sacrement</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de l'Hopital Laval</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2006</study_first_submitted>
  <study_first_submitted_qc>May 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2006</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smokers</keyword>
  <keyword>Adults</keyword>
  <keyword>Inflammatory markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

